Novartis tests new shot for weakened hearts
NCT ID NCT05328752
Summary
This early-stage study tested the safety and side effects of a new drug called XXB750 for people with chronic heart failure. It involved 27 participants who received either the drug or a placebo via injection. The main goal was to see how well the drug was tolerated and how it moved through the body, not to measure how well it treated the heart condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fairview Health Services .
Saint Paul, Minnesota, 55102, United States
-
Jacksonville Ctr for Clin Rea Main Centre
Jacksonville, Florida, 32216, United States
-
Nature Coast Clinical Research LLC
Inverness, Florida, 34452, United States
-
Novartis Investigative Site
Groningen, 9713 GZ, Netherlands
Conditions
Explore the condition pages connected to this study.